TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33930329

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study: 33979736

Group type: EXPERIMENTAL
Intervention: Nomograms developed to predict overall survival (OS) and cancer-specific survival (CSS)
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Nomograms compared to the Tumor-Node-Metastasis (TNM) staging system
Number of subjects: 1781
Study: 36434164

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT) with 60-72 Gy ± ADT
Number of subjects: 3510

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT)
Number of subjects: 3510
Study: 34555048

Group type: EXPERIMENTAL
Intervention: Advanced self-care with disinfectant using a custom-fabricated prescription tray applied twice a day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care for periodontal diseases
Number of subjects: 110
Study: 34554352

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) belimumab 10 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Subcutaneous (SC) belimumab 200 mg
Number of subjects: 36
Study: 32977137

Group type: EXPERIMENTAL
Intervention: Therapeutic enoxaparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prophylactic anticoagulation
Number of subjects: 20
Study: 35689904

Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with DAF (1 mA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham tDCS combined with DAF
Number of subjects: 50
Study: 33892676

Group type: EXPERIMENTAL
Intervention: Genomic signature based nomogram using 23-RNA signatures
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Genomic signature based nomogram
Number of subjects: 300
Study: 34399976

Group type: EXPERIMENTAL
Intervention: Meal planning skills
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mealtime routines
Number of subjects: 108
Study: 32725799

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36197647

Group type: EXPERIMENTAL
Intervention: Genicular nerve block (GNB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intra-articular triamcinolone (TA)
Number of subjects: 104
Study: 33609174

Group type: EXPERIMENTAL
Intervention: Breakfast (ready‐to‐eat‐cereal [RTEC] and milk, up to 70 g of cereal and 300 ml of milk)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Breakfast (ready‐to‐eat‐cereal [RTEC] and milk)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No Breakfast
Number of subjects: 234
Study: 35289296

Group type: EXPERIMENTAL
Intervention: Triple Therapy (TT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: DTG/3TC
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: DRVc/3TC
Number of subjects: 151
Study: 32307061

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 33253910

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose‐derived mesenchymal stem cells (ASCs) injected into the lacrimal gland (LG)
Number of subjects: 7
Study: 32390720

Group type: EXPERIMENTAL
Intervention: WB-EMS training with 20 Hz (T20)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: WB-EMS training with 85 Hz (T85)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Inactive control group (CON)
Number of subjects: 51
Study: 34200105

Group type: EXPERIMENTAL
Intervention: Combined calcium and inulin supplementation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcium supplementation alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inulin supplementation alone
Number of subjects: 12
Study: 33262202

Group type: EXPERIMENTAL
Intervention: ODM-203 400 mg/day
Number of subjects: 84
Study: 35180229

Group type: EXPERIMENTAL
Intervention: Goal Management Training (Adapted-GMT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Psychoeducation combined with mindfulness exercises (PSYCH-Mind)
Number of subjects: 12
Study: 33739155

Group type: EXPERIMENTAL
Intervention: AndroForte5 (testosterone 5.0% wt/vol, 100 mg/2 mL) cream (T) + supervised center-based exercise (Ex)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Placebo (P) + supervised center-based exercise (Ex)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AndroForte5 (T) + no additional exercise (NEx)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (P) + no additional exercise (NEx)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AndroForte5 (T) + supervised center-based exercise (Ex)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise training (Ex)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (T)
Number of subjects: 80
Study: 32853015

Group type: EXPERIMENTAL
Intervention: Trauma Center Trauma-Sensitive Yoga (TCTSY)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Active control (women's health education)
Number of subjects: 64
Study: 35300378

Group type: EXPERIMENTAL
Intervention: Konjaku flour (KF)
Number of subjects: 69
Study: 33287758

Group type: EXPERIMENTAL
Intervention: Extended chemotherapy (>6 cycles, n = 52)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard chemotherapy (6 cycles, n = 83)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Extended chemotherapy (>6 cycles)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard chemotherapy (6 cycles)
Number of subjects: 135
Study: 32633648

Group type: EXPERIMENTAL
Intervention: Eggshell membrane (EM) 300 mg daily for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 34963630

Group type: EXPERIMENTAL
Intervention: Decompression alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Decompression plus fusion
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Decompression plus stabilization
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fusion
Number of subjects: 85
Study: 34081901

Group type: EXPERIMENTAL
Intervention: ATF3 inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous nucleotide supplementation
Number of subjects: 0
Study: 33630649

Group type: EXPERIMENTAL
Intervention: A‐EFT intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vivid Memory Task (VMT) control
Number of subjects: 45
Study: 33175291

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol 5/5 μg
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Tiotropium 5 μg
Number of subjects: 2055
Study: 35806897

Group type: EXPERIMENTAL
Intervention: High-fiber diet rich in polyunsaturated fatty acids (PUFAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard nutritional recommendations
Number of subjects: 0
Study: 32393169

Group type: COMPARATOR
Intervention: Fastrach
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ILTS-D2
Number of subjects: 126
Study: 32744215

Group type: EXPERIMENTAL
Intervention: Hands-on, teaching kitchen culinary education class (n = 18)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-kitchen-based dietary counselling (n = 23)
Number of subjects: 41
Study: 35220313

Group type: EXPERIMENTAL
Intervention: High dairy (HD) - ≥4 servings/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Adequate dairy (AD) - ≤2 servings/day
Number of subjects: 24
Study: 32103645

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sunlight exposure (20% to 30% of body surface areas for 30‐60 minutes per day, 3 times a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Daily living (control group)
Number of subjects: 60
Study: 35526530

Group type: EXPERIMENTAL
Intervention: Phentermine (15 mg once daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33577697

Group type: EXPERIMENTAL
Intervention: Rayner RAO800C IOL
Number of subjects: 68
Study: 36630846

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 40
Study: 33820680

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 33780940

Group type: EXPERIMENTAL
Intervention: Coaching to Increase Water Intake (CIWI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Same water intake (control)
Number of subjects: 124
Study: 35287681

Group type: EXPERIMENTAL
Intervention: Self-care training program in physical, psychological, social and sexual dimensions in 5 sessions during a week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine care and training (control group)
Number of subjects: 70
Study: 32855069

Group type: EXPERIMENTAL
Intervention: Salt substitution (reduced-sodium, added-potassium alternative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salt substitution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing large-scale randomised trial
Number of subjects: 0
Study: 35982326

Group type: EXPERIMENTAL
Intervention: Circumferential periosteal block (CPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hematoma block (HB)
Number of subjects: 50
Study: 34975078

Group type: EXPERIMENTAL
Intervention: 2% lignocaine medicated pad (LMP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 200
Study: 32342139

Group type: EXPERIMENTAL
Intervention: Strengthening (ST) group, n=28
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Strengthening + Balance (ST + B) group, n=28
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group, n=26
Number of subjects: 82
Study: 616914772

Group type: EXPERIMENTAL
Intervention: PCVC therapy (paracentesis with central venous catheter, draining 1-2 L ascites every 1 or 2 days)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: PCVC therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (diuretic therapy)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 33823907

Group type: EXPERIMENTAL
Intervention: Intervention arm A offering HIV treatment irrespective of CD4 count
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Intervention arm B following national guidelines for universal treatment
Number of subjects: 1547
Study: 35442974

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study: 36121655

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual treatment (control)
Number of subjects: 80
Study: 33116094

Group type: EXPERIMENTAL
Intervention: Massage therapy and phototherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phototherapy only
Number of subjects: 100
Study: 34923602

Group type: EXPERIMENTAL
Intervention: Lyft 10 mg NP
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Other NPs (not specified)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cigarette
Number of subjects: 35
Study: 37193566

Group type: EXPERIMENTAL
Intervention: LEMBOREXANT 5 mg (LEM5)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: LEMBOREXANT 10 mg (LEM10)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 35311722

Group type: EXPERIMENTAL
Intervention: Inclined treadmill training
Number of subjects: 18
Study: 32107736

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (resistance and aerobic)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home-based intervention following supervised exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Printed exercise material and recommendation to exercise
Number of subjects: 100
Study: 36041991

Group type: EXPERIMENTAL
Intervention: Self-reflection
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study: 33596356

Group type: EXPERIMENTAL
Intervention: Avacopan (30 mg twice daily)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Prednisone (tapering schedule)
Number of subjects: 331
Study: 32744862

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Pooled Canakinumab groups
Number of subjects: 10061

Group type: COMPARATOR
Intervention: N/A (Placebo)
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: N/A (Secondary endpoint)
Number of subjects: 10061
Study: 35307223

Group type: EXPERIMENTAL
Intervention: Echocardiographic stroke volume index and cardiac index in patients with LV ejection fraction <40%
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Low perfusion score combined with echocardiographic LV output parameters in patients with LV ejection fraction <40%
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Low perfusion score in patients with LV ejection fraction ≥40%
Number of subjects: 303
Study: 33797199

Group type: EXPERIMENTAL
Intervention: IOERT (10 Gy) followed by HWBI (42.56 Gy in 16 fractions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CWBI (50 Gy in 25 fractions) followed by EETBB (10 Gy in 5 fractions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (IOERT+HWBI and CWBI+EETBB)
Number of subjects: 60
Study: 32915900

Group type: COMPARATOR
Intervention: Hemosol B0 (no potassium or phosphate)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Hemosol B0 and potassium‐containing solution (MultiBic)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Phosphate‐ and potassium‐containing solution (Phoxilium), Hemosol B2, Prismasol 2, and Prismasol 4
Number of subjects: 324
Study: 33118421

Group type: EXPERIMENTAL
Intervention: Daily intake of NZBC extract (210 mg of anthocyanins, CurraNZ™) for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Every-other-day intake of NZBC extract for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (no NZBC extract)
Number of subjects: 16
Study: 33077355

Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 1119
Study: 33512980

Group type: EXPERIMENTAL
Intervention: NMES (neuromuscular electrical stimulation) applied to quadriceps muscles, 5 days per week for 4 weeks.
Number of subjects: 37

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 37
Study: 36178918

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation for 15 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 0
Study: 33517323

Group type: EXPERIMENTAL
Intervention: 18F‐fluciclovine PET/CT (Arm B)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional imaging (CI) only (Arm A)
Number of subjects: 165
Study: 32819960

Group type: EXPERIMENTAL
Intervention: Usual primary care for LBP and an internet intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual primary care for LBP and an internet intervention with additional physiotherapist telephone support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual primary care for LBP
Number of subjects: 0
Study: 35630085

Group type: EXPERIMENTAL
Intervention: 150 mg clindamycin every 8 h for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg clindamycin every 8 h for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg clindamycin every 12 h for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin concentration in saliva
Number of subjects: 0
Study: 34037885

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (50 mg/kg/day for 10 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34789054

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training (4 sets of 30 seconds sprints)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Leg press training (4 sets of 10-12 repetitions to momentary failure)
Number of subjects: 25
Study: 33904913

Group type: EXPERIMENTAL
Intervention: PCL-C (DSM-IV criteria)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: PCL-5 (DSM-5 criteria)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: PCL-C (for DSM-IV criteria)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: PCL-5 (for DSM-5 criteria)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: PCL-C and PCL-5
Number of subjects: 1921
Study: 32918853

Group type: EXPERIMENTAL
Intervention: MedDiet-VOO (n = 120)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: MedDiet-Nuts (n = 119)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: MedDiet adherence increments
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control diet (n = 119)
Number of subjects: 358
Study: 34449355

Group type: EXPERIMENTAL
Intervention: Active transcutaneous cervical vagus nerve stimulation (tcVNS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham transcutaneous cervical vagus nerve stimulation (tcVNS)
Number of subjects: 50
Study: 34844625

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy plus home stretching exercises
Number of subjects: 131

Group type: COMPARATOR
Intervention: Home stretching exercises alone
Number of subjects: 131
Study: 34923903

Group type: EXPERIMENTAL
Intervention: Probiotics (Prob) + Berberine (BBR)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Berberine (BBR) alone
Number of subjects: 365

Group type: COMPARATOR
Intervention: Probiotics (Prob) alone
Number of subjects: 365
Study: 32540779

Group type: EXPERIMENTAL
Intervention: 4-flap Z-frenuloplasty
Number of subjects: 37

Group type: COMPARATOR
Intervention: simple frenotomy
Number of subjects: 37
Study: 34047410

Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Omnidirectional deep brain stimulation (DBS)
Number of subjects: 234
Study: 33346587

Group type: EXPERIMENTAL
Intervention: Higher concentrations of Lactobacillus crispatus
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 34369667

Group type: COMPARATOR
Intervention: PF-06730512 (up to 1000 mg IV single ascending dose)
Number of subjects: 79

Group type: COMPARATOR
Intervention: PF-06730512 (up to 400 mg SC multiple ascending doses)
Number of subjects: 79

Group type: COMPARATOR
Intervention: PF-06730512 (up to 1000 mg IV multiple ascending doses)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (IV and SC)
Number of subjects: 79
Study: 34001230

Group type: EXPERIMENTAL
Intervention: Food for Mind (FM) nutrition intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bring Good Mood (BGM) social support control group
Number of subjects: 144
Study: 32521324

Group type: EXPERIMENTAL
Intervention: Nurse-led program of systematic screening for comorbidities
Number of subjects: 502
Study: 35533322

Group type: EXPERIMENTAL
Intervention: Acupressure for 3 minutes every day for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical abdominal massage for 15‐20 minutes every day for 5 days
Number of subjects: 60
Study: 36151279

Group type: EXPERIMENTAL
Intervention: Revitalisation technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)-based technique
Number of subjects: 20
Study: 33486783

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET)
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Endocrine therapy (ET)
Number of subjects: 1343
Study: 33726735

Group type: EXPERIMENTAL
Intervention: Incremental patient benefit
Number of subjects: 606

Group type: COMPARATOR
Intervention: Incremental cost-effectiveness ratio (ICER)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Price magnitude framing
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Relevance of patient
Number of subjects: 606
Study: 32873443

Group type: EXPERIMENTAL
Intervention: Foot reflexology massage (20 min for 3 days, 15 min before changing wound dressings)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 52
Study: 34543419

Group type: EXPERIMENTAL
Intervention: Relative weekly change of progression >10% in running volume and progression in running pace
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Absolute weekly change of progression >5 km in running volume and progression in running pace
Number of subjects: 586
Study: 34671676

Group type: EXPERIMENTAL
Intervention: Oral synthetic vitamin E (400 IU/day) for eight weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 33874898

Group type: COMPARATOR
Intervention: IV normal saline (Group C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 mg/kg IV aminophylline (Group A1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 mg/kg IV aminophylline (Group A2)
Number of subjects: 45
Study: 32091536

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 4044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4044
Study: 36165994

Group type: EXPERIMENTAL
Intervention: Jump training with overhead goal (OG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Jump training without overhead goal (OG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 52
Study: 34244155

Group type: EXPERIMENTAL
Intervention: ω‐3‐FA (3.25 g/day combined EPA and DHA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ω‐3‐FA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ω‐3‐FA (for those with >10% weight loss)
Number of subjects: 46
Study: 32908891

Group type: EXPERIMENTAL
Intervention: CLOCK gene rs1801260 (TC) and positive psychological symptoms
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: CLOCK gene rs1801260 (TT)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Positive psychological symptoms
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Different genotypes at CLOCK rs1801260 and rs6850524
Number of subjects: 521
Study: 35681224

Group type: EXPERIMENTAL
Intervention: MULTIPAP Plus intervention
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1148